Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide

de Boer-Dennert M, de Wit R, Schmitz PI et al (1997) Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 76:1055–1061

Hickok JT, Roscoe JA, Morrow GR et al (2003) Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer 97:2880–2886 doi: 10.1002/cncr.11408

Pollera CF, Giannarelli D (1989) Prognostic factors influencing cisplatin-induced emesis: definition and validation of a predictive logistic model. Cancer 64:1117–1122 doi: 10.1002/1097-0142(19890901)64:5<1117::AID-CNCR2820640525>3.0.CO;2-R

du Bois A, Meerpohl HG, Vach W et al (1992) Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron. Eur J Cancer 28:450–457 doi: 10.1016/S0959-8049(05)80075-9

Hesketh P, Navari R, Grote T et al (1996) Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol 14:2242–2249

Hesketh PJ, Kris MG, Grunberg SM et al (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103–109

DiBenedetto J Jr, Cubeddu LX, Ryan T et al (1995) Ondansetron for nausea and vomiting associated with moderately emetogenic cancer chemotherapy. Clin Ther 17:1091–1098 doi: 10.1016/0149-2918(95)80087-5

Gralla RJ, Osoba D, Kris MG et al (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17:2971–2994

Hesketh PJ, Grunberg SM, Gralla RJ et al (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112–4119 doi: 10.1200/JCO.2003.01.095

Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al (2003) Addition of the neurokinin-1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090–3098 doi: 10.1002/cncr.11433

Warr DG, Hesketh PJ, Gralla RJ et al (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822–2830, (Erratum, J Clin Oncol 2005; 23:5851) doi: 10.1200/JCO.2005.09.050

Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358:2482–2494 doi: 10.1056/NEJMra0706547

Perez EA (1999) 5-HT3 antiemetic therapy for patients with breast cancer. Breast Cancer Res Treat 57:207–214 doi: 10.1023/A:1006233802863

Beck TM, Ciociola AA, Jones SE et al (1993) Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. The Ondansetron Study Group. Ann Intern Med 118:407–413

Hesketh PJ (1994) Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists. Support Care Cancer 2:286–292 doi: 10.1007/BF00365579

Hesketh PJ (2000) Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest 18:163–173 doi: 10.3109/07357900009038248

Roila F, Hesketh PJ, Herrstedt J et al (2006) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17:20–28 doi: 10.1093/annonc/mdj936

Kris MG, Hesketh PJ, Somerfield MR et al (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24:2932–2947, (Erratum, J Clin Oncol 2006; 24:5341–5342) doi: 10.1200/JCO.2006.06.9591

Ettinger DS, Bierman PJ, Bradbury B et al (2007) Antiemesis. J Natl Compr Canc Netw 5:12–33

Herrstedt J (2007) Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis. Ann Oncol 18(Suppl 2):ii83–ii85 doi: 10.1093/annonc/mdm050

Vermeulen LC Jr, Matuszewski KA, Ratko TA et al (1994) Evaluation of ondansetron prescribing in US academic medical centers. Arch Intern Med 154:1733–1740 doi: 10.1001/archinte.154.15.1733

Fabi A, Barduagni M, Lauro S et al (2003) Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? An observational study. Support Care Cancer 11:156–161

Drug Utilization Review Team in Oncology (DURTO) (2003) Antiemetic prescription in Italian breast cancer patients submitted to adjuvant chemotherapy. Support Care Cancer 11:785–789 doi: 10.1007/s00520-003-0478-0

Kaiser R (2005) Antiemetic guidelines: are they being used? Lancet Oncol 6:622–625 doi: 10.1016/S1470-2045(05)70284-9

Oechsle K, Muller M, Hartmann J et al (2006) Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT3 antagonists and dexamethasone. Onkologie 29:557–561 doi: 10.1159/000096689